Congress mandates anthrax defense plan, locks in long-term pharma contracts
H.R. 2707 — Protecting American Families and Servicemembers from Anthrax Act · Filed by Donald Davis (D-NC) · 19 cosponsors · Introduced Apr 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Departments of Health and Human Services and Defense to jointly develop a 10-year strategy within 180 days for maintaining and replenishing anthrax countermeasures (drugs, vaccines, and treatments) in the Strategic National Stockpile and military supplies. The bill mandates annual reporting to Congress on anthrax threats, federal programs addressing them, and efforts to ensure adequate countermeasures for military dependents, with a focus on manufacturer sustainability and innovation.
Why we flagged it
The bill's core mechanism is a directive to federal agencies to develop and maintain a strategic defense plan against anthrax threats, with mandatory reporting. This is a straightforward public health and national security measure, not a regulatory carve-out or appropriation.
What the text implies
- The bill's focus on 'manufacturer sustainability and innovation' may create implicit pressure to award contracts or favorable procurement terms to anthrax countermeasure manufacturers, potentially inflating costs or limiting competitive bidding.
- Annual classified reporting to Congress may obscure budget allocations and procurement decisions from public scrutiny, reducing transparency despite the bill's stated accountability purpose.
- The 10-year strategy requirement locks in long-term commitments to specific countermeasures and manufacturers without explicit sunset or re-evaluation triggers, potentially entrenching vendor relationships.
- Military dependents on foreign installations are explicitly included in the mandate, expanding the scope and cost of the program beyond domestic civilian preparedness.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill mandates public health preparedness planning for a serious bioterrorism threat and requires transparent reporting to Congress, strengthening civilian and military readiness without imposing new costs or restrictions on citizens. The focus on sustained stockpiling and countermeasure availability directly protects public health.
Who stands to gain
- anthrax countermeasure manufacturers
- pharmaceutical and biological product companies with FDA-approved anthrax treatments
- defense contractors involved in military medical countermeasure supply chains
Named in the bill
Department of Health and Human Services, Department of Defense, Food and Drug Administration, Strategic National Stockpile, Public Health Emergency Medical Countermeasures Enterprise, Assistant Secretary for Preparedness and Response, Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs, House Committee on Energy and Commerce, House Committee on Appropriations, Senate Committee on Appropriations, House Committee on Armed Services, Senate Committee on Armed Services — and 1 more
Where it stands
19 cosponsors: 14 Republicans, 5 Democrats.
- Apr 8, 2025 — Introduced · Congress.gov: “Introduced in House”
- Apr 8, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Armed Services · Congress.gov: “Referred to the Committee on Armed Services, and in addition to the Committee on Energy and Commerce, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $318,000 in lobbying spend. A filing names 1 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Donald Davis, the sponsor, reported $1,617,446 in PAC receipts in the 2026 cycle.
- Elusys Therapeutics Inc Fka Nighthawk Biosciences, Inc. — $280,000 on 1 filing
- Elusys Theraputics — $38,000 on 2 filings
Lobbying Disclosure Act filings through Jul 18, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,825 characters) on Aug 20, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 18, 2026 · page rendered 2026-10-20.
“Congress mandates anthrax defense plan, locks in long-term pharma contracts” QuorumCivic. https://share.quorumcivic.app/bill/119/hr2707 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.